Aligos Therapeutics, Inc. (ALGS)
2.15
-0.42
(-16.34%)
USD |
NASDAQ |
Nov 11, 16:00
2.09
-0.06
(-2.79%)
After-Hours: 19:59
Aligos Therapeutics Net Income (Quarterly) : -21.86M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -21.86M |
| June 30, 2026 | -1.504M |
| March 31, 2026 | -23.04M |
| December 31, 2025 | -19.88M |
| September 30, 2025 | -31.54M |
| June 30, 2025 | -15.86M |
| March 31, 2025 | 43.09M |
| December 31, 2024 | -82.15M |
| September 30, 2024 | -19.26M |
| June 30, 2024 | 5.061M |
| March 31, 2024 | -34.86M |
| December 31, 2023 | -27.89M |
| September 30, 2023 | -18.04M |
| Date | Value |
|---|---|
| June 30, 2023 | -18.79M |
| March 31, 2023 | -22.96M |
| December 31, 2022 | -21.89M |
| September 30, 2022 | -18.62M |
| June 30, 2022 | -19.92M |
| March 31, 2022 | -35.62M |
| December 31, 2021 | -37.71M |
| September 30, 2021 | -33.12M |
| June 30, 2021 | -29.82M |
| March 31, 2021 | -27.67M |
| December 31, 2020 | -34.42M |
| September 30, 2020 | -33.30M |
| June 30, 2020 | -33.30M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | 1.567M |
| Amgen, Inc. | 3.864B |
| Anika Therapeutics, Inc. | -0.311M |
| BioCryst Pharmaceuticals, Inc. | 37.92M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 2.869M |
| Total Expenses (Quarterly) | 24.73M |
| EPS Diluted (Quarterly) | -2.090 |
| Enterprise Value | -3.781M |
| Gross Profit Margin (Quarterly) | 91.25% |
| Profit Margin (Quarterly) | -761.9% |
| Earnings Yield | -296.0% |
| Normalized Earnings Yield | -320.26 |